Who is the CEO of allarity Therapeutics Inc?

Noi, Yahoo, facem parte din familia de mărci Yahoo.

Când folosiți site-urile și aplicațiile noastre, noi folosimmodule cookie în următoarele scopuri:

How many employees does Allarity Therapeutics have?

Amgen (AMGN) United States $137.593B 14.48 Bristol Myers Squibb (BMY) United States $124.615B 7.84 Gilead Sciences (GILD) United States $96.329B 12.31 Regeneron Pharmaceuticals (REGN) United States $89.697B 21.65 Vertex Pharmaceuticals (VRTX) United States $89.518B 26.38 CSL (CSLLY) Australia $83.614B 0.00 GSK (GSK) United Kingdom $75.266B 10.21 Moderna (MRNA) United States $41.329B 40.07 Seagen (SGEN) United States $38.655B 0.00 Biogen (BIIB) United States $37.062B 15.76 Argenex SE (ARGX) Netherlands $30.194B 0.00 BioNTech SE (BNTX) Germany $27.292B 6.35 Alnylam Pharmaceuticals (ALNY) United States $26.456B 0.00 Horizon Therapeutics Public (HZNP) Ireland $26.396B 25.67 Genmab (GMAB) Denmark $23.979B 36.31 Illumina (ILMN) United States $23.867B 171.33 BeiGene (BGNE) Cayman Islands $19.376B 0.00 BioMarin Pharmaceutical (BMRN) United States $17.241B 91.62 Exact Sciences (EXAS) United States $14.164B 0.00 Incyte (INCY) United States $14.140B 34.48 Verona Pharma American Depositary Share (VRNA) United Kingdom $11.633B 0.00 Bio-Techne Corp (TECH) United States $11.466B 40.90 Bio-Rad Laboratories (BIO.B) United States $11.268B 31.64 Legend Biotech (LEGN) United States $10.792B 0.00 Sarepta Therapeutics (SRPT) United States $10.470B 0.00 QIAGEN (QGEN) Netherlands $9.533B 20.10 Repligen (RGEN) United States $8.864B 60.68 Roivant Sciences (ROIV) United Kingdom $8.613B 0.00 Exelixis (EXEL) United States $7.055B 43.45 Sino Biopharmaceutical (SBMFF) Hong Kong, SAR China $6.961B 0.00 Karuna Therapeutics (KRTX) United States $6.901B 0.00 Reata Pharmaceuticals (RETA) United States $6.562B 0.00 Swedish Orphan Biovitrum (BIOVF) Sweden $5.888B 19.00 Ascendis Pharma (ASND) Denmark $5.747B 0.00 Intra-Cellular Therapies (ITCI) United States $5.494B 0.00 Halozyme Therapeutics (HALO) United States $5.413B 18.24 Apellis Pharmaceuticals (APLS) United States $5.005B 0.00 Alkermes (ALKS) Ireland $4.965B 248.42 Vaxcyte (PCVX) United States $4.859B 0.00 Ginkgo Bioworks Holdings (DNA) United States $4.240B 0.00 ACADIA Pharmaceuticals (ACAD) United States $4.239B 0.00 CRISPR Therapeutics AG (CRSP) Switzerland $3.920B 0.00 Guardant Health (GH) United States $3.796B 0.00 Insmed (INSM) United States $3.782B 0.00 Amicus Therapeutics (FOLD) United States $3.724B 0.00 Axsome Therapeutics (AXSM) United States $3.633B 0.00 MoonLake Immunotherapeutics (MLTX) Switzerland $3.599B 0.00 Krystal Biotech (KRYS) United States $3.454B 0.00 Cytokinetics (CYTK) United States $3.344B 0.00 Denali Therapeutics (DNLI) United States $3.284B 0.00 Blueprint Medicines (BPMC) United States $3.150B 0.00 Intellia Therapeutics (NTLA) United States $3.141B 0.00 Ultragenyx Pharmaceutical (RARE) United States $2.928B 0.00 Prothena (PRTA) Ireland $2.890B 0.00 Immunovant (IMVT) United States $2.823B 0.00 Akero Therapeutics (AKRO) United States $2.798B 0.00 Nuvalent (NUVL) United States $2.688B 0.00 Immunocore Holdings (IMCR) United Kingdom $2.602B 0.00 Fortrea Holdings (FTRE) United States $2.559B 0.00 Morphic Holding (MORF) United States $2.549B 0.00 HUTCHMED (China) (HCM) Hong Kong, SAR China $2.526B 0.00 Zai Lab (ZLAB) China $2.500B 0.00 Galapagos (GLPG) Belgium $2.379B 0.00 Xenon Pharmaceuticals (XENE) Canada $2.371B 0.00 Certara (CERT) United States $2.318B 38.18 Harmony Biosciences Holdings (HRMY) United States $2.287B 12.71 Zealand Pharma (ZLDPF) Denmark $2.149B 0.00 Ventyx Biosciences (VTYX) United States $2.000B 0.00 Mirati Therapeutics (MRTX) United States $1.995B 0.00 Beam Therapeutics (BEAM) United States $1.982B 0.00 CureVac (CVAC) Germany $1.791B 0.00 Dynavax Technologies (DVAX) United States $1.762B 19.00 NeoGenomics (NEO) United States $1.750B 0.00 Vericel (VCEL) United States $1.749B 0.00 Zentalis Pharmaceuticals (ZNTL) United States $1.712B 0.00 Rocket Pharmaceuticals (RCKT) United States $1.710B 0.00 IDEAYA Biosciences (IDYA) United States $1.680B 0.00 SpringWorks Therapeutics (SWTX) United States $1.666B 0.00 Arcellx (ACLX) United States $1.617B 0.00 Bavarian Nordic (BVNRY) Denmark $1.557B 9.38 Arcus Biosciences (RCUS) United States $1.544B 0.00 AbCellera Biologics (ABCL) Canada $1.519B 0.00 Viking Therapeutics (VKTX) United States $1.515B 0.00 Revance Therapeutics (RVNC) United States $1.497B 0.00 Arvinas (ARVN) United States $1.430B 0.00 Rhythm Pharmaceuticals (RYTM) United States $1.400B 0.00 Iovance Biotherapeutics (IOVA) United States $1.347B 0.00 Vir Biotechnology (VIR) United States $1.343B 0.00 Twist Bioscience (TWST) United States $1.323B 0.00 Myriad Genetics (MYGN) United States $1.310B 0.00 Biohaven (BHVN) United States $1.299B 0.00 Celldex Therapeutics (CLDX) United States $1.296B 0.00 Day One Biopharmaceuticals (DAWN) United States $1.292B 0.00 89BIO (ETNB) United States $1.291B 0.00 ANI Pharmaceuticals (ANIP) United States $1.275B 20.40 Prime Medicine (PRME) United States $1.228B 0.00 Disc Medicine (IRON) United States $1.215B 0.00 Merus (MRUS) Netherlands $1.203B 0.00 Kiniksa Pharmaceuticals (KNSA) Bermuda $1.187B 31.92 Syndax Pharmaceuticals (SNDX) United States $1.182B 0.00 Geron (GERN) United States $1.178B 0.00 MannKind (MNKD) United States $1.154B 0.00 Structure Therapeutics (GPCR) United States $1.148B 0.00 Mirum Pharmaceuticals (MIRM) United States $1.147B 0.00 Replimune (REPL) United States $1.104B 0.00 Apogee Therapeutics (APGE) United States $1.098B 0.00 Ligand Pharmaceuticals (LGND) United States $1.089B 24.13 Kymera Therapeutics (KYMR) United States $1.076B 0.00 Protagonist Therapeutics (PTGX) United States $1.061B 0.00 Deciphera Pharmaceuticals (DCPH) United States $1.051B 0.00 Keros Therapeutics (KROS) United States $1.048B 0.00 ACELYRIN, INC (SLRN) United States $1.041B 0.00 Travere Therapeutics (TVTX) United States $1.020B 0.00 Sana Biotechnology (SANA) United States $1.011B 0.00 Cytek Biosciences (CTKB) United States $0.990B 0.00 Pliant Therapeutics (PLRX) United States $0.984B 0.00 Cogent Biosciences (COGT) United States $0.983B 0.00 Adaptive Biotechnologies (ADPT) United States $0.949B 0.00 Immatics (IMTX) Germany $0.910B 0.00 Inhibrx (INBX) United States $0.887B 0.00 MiMedx (MDXG) United States $0.884B 0.00 ADMA Biologics Inc (ADMA) United States $0.852B 0.00 Pharming Group (PHAR) Netherlands $0.851B 0.00 Belite Bio (BLTE) United States $0.840B 0.00 Tango Therapeutics (TNGX) United States $0.818B 0.00 Pharming Group (PHGUF) Netherlands $0.802B 30.75 Adaptimmune Therapeutics (ADAP) United Kingdom $0.799B 0.00 REGENXBIO (RGNX) United States $0.792B 0.00 POINT Biopharma Global (PNT) United States $0.788B 8.56 Arcturus Therapeutics Holdings (ARCT) United States $0.776B 15.36 Northwest Biotherapeutics (NWBO) United States $0.775B 0.00 ImmunityBio (IBRX) United States $0.748B 0.00 Vera Therapeutics (VERA) United States $0.746B 0.00 Phathom Pharmaceuticals (PHAT) United States $0.737B 0.00 PureTech Health (PRTC) United States $0.736B 0.00 Viridian Therapeutics (VRDN) United States $0.731B 0.00 Kura Oncology (KURA) United States $0.724B 0.00 Novavax (NVAX) United States $0.695B 0.00 Editas Medicine (EDIT) United States $0.691B 0.00 Ambrx Biopharma (AMAM) United States $0.689B 0.00 Rapt Therapeutics (RAPT) United States $0.658B 0.00 Allogene Therapeutics (ALLO) United States $0.650B 0.00 Avid Bioservices (CDMO) United States $0.650B 0.00 Sinovac Biotech (SVA) China $0.644B 0.00 Tyra Biosciences (TYRA) United States $0.635B 0.00 Anavex Life Sciences (AVXL) United States $0.628B 0.00 Pharma Mar (PHMMF) Spain $0.621B 0.00 Bicycle Therapeutics (BCYC) United Kingdom $0.613B 0.00 Basilea Pharmaceutica AG (BPMUF) Switzerland $0.593B 0.00 Cabaletta Bio (CABA) United States $0.579B 0.00 Biomea Fusion (BMEA) United States $0.528B 0.00 Avidity Biosciences (RNA) United States $0.527B 0.00 Genelux (GNLX) United States $0.522B 0.00 HilleVax (HLVX) United States $0.520B 0.00 AnaptysBio (ANAB) United States $0.518B 0.00 23andMe Holding (ME) United States $0.515B 0.00 Alector (ALEC) United States $0.513B 0.00 Olema Pharmaceuticals (OLMA) United States $0.499B 0.00 Autolus Therapeutics (AUTL) United Kingdom $0.498B 0.00 Castle Biosciences (CSTL) United States $0.496B 0.00 Caribou Biosciences (CRBU) United States $0.494B 0.00 WAVE Life Sciences (WVE) Singapore $0.494B 0.00 Agenus (AGEN) United States $0.493B 0.00 Mineralys Therapeutics (MLYS) United States $0.491B 0.00 Tarsus Pharmaceuticals (TARS) United States $0.489B 0.00 Intercept Pharmaceuticals (ICPT) United States $0.488B 0.00 Entrada Therapeutics (TRDA) United States $0.477B 0.00 Janux Therapeutics (JANX) United States $0.473B 0.00 Zymeworks (ZYME) United States $0.465B 2.45 Arcutis Biotherapeutics (ARQT) United States $0.462B 0.00 Liquidia Technologies (LQDA) United States $0.450B 0.00 Oric Pharmaceuticals (ORIC) United States $0.449B 0.00 Oculis Holding AG (OCS) Switzerland $0.448B 0.00 Coherus BioSciences (CHRS) United States $0.442B 0.00 ITeos Therapeutics (ITOS) United States $0.441B 0.00 Nurix Therapeutics (NRIX) United States $0.431B 0.00 Repare Therapeutics (RPTX) Canada $0.425B 0.00 Cullinan Oncology (CGEM) United States $0.421B 0.00 IGM Biosciences (IGMS) United States $0.420B 0.00 Nautilus Biotechnology (NAUT) United States $0.419B 0.00 Edgewise Therapeutics (EWTX) United States $0.404B 0.00 Humacyte (HUMA) United States $0.402B 0.00 Amarin (AMRN) Ireland $0.398B 0.00 Erasca (ERAS) United States $0.390B 0.00 Aura Biosciences (AURA) United States $0.385B 0.00 Seres Therapeutics (MCRB) United States $0.379B 0.00 EYEPOINT PHARMACEUTICALS, INC (EYPT) United States $0.378B 0.00 Aerovate Therapeutics (AVTE) United States $0.378B 0.00 Precigen (PGEN) United States $0.373B 0.00 Urogen Pharma (URGN) United States $0.367B 0.00 UniQure (QURE) Netherlands $0.367B 0.00 MaxCyte (MXCT) United States $0.364B 0.00 Icosavax (ICVX) United States $0.361B 0.00 Voyager Therapeutics (VYGR) United States $0.359B 3.60 Bluebird Bio (BLUE) United States $0.356B 0.00 Oxford BioMedica (OXBDF) United Kingdom $0.352B 0.00 MeiraGTx Holdings (MGTX) United States $0.351B 0.00 Lexicon Pharmaceuticals (LXRX) United States $0.345B 0.00 Arbutus Biopharma (ABUS) United States $0.343B 0.00 Apollomics (APLM) Taiwan $0.343B 0.00 Scholar Rock Holding (SRRK) United States $0.342B 0.00 Scilex Holding (SCLX) United States $0.332B 0.00 AN2 Therapeutics (ANTX) United States $0.326B 0.00 Acumen Pharmaceuticals (ABOS) United States $0.319B 0.00 Nuvation Bio (NUVB) United States $0.315B 0.00 Terns Pharmaceuticals (TERN) United States $0.313B 0.00 Zura Bio (ZURA) United States $0.300B 0.00 Monte Rosa Therapeutics (GLUE) United States $0.297B 0.00 Fulcrum Therapeutics (FULC) United States $0.294B 0.00 DBV Technologies S.A (DBVT) France $0.293B 0.00 Sutro Biopharma (STRO) United States $0.281B 0.00 Compass Therapeutics (CMPX) United States $0.277B 0.00 Atea Pharmaceuticals (AVIR) United States $0.275B 0.00 Vanda Pharmaceuticals (VNDA) United States $0.273B 17.59 AC Immune (ACIU) Switzerland $0.271B 0.00 Inozyme Pharma (INZY) United States $0.264B 0.00 Ovid Therapeutics (OVID) United States $0.258B 0.00 Sagimet Biosciences (SGMT) United States $0.256B 0.00 ScPharmaceuticals (SCPH) United States $0.256B 0.00 Anika Therapeutics (ANIK) United States $0.255B 0.00 Third Harmonic Bio (THRD) United States $0.251B 0.00 Innate Pharma S.A (IPHA) France $0.246B 0.00 Astria Therapeutics (ATXS) United States $0.241B 0.00 Verastem (VSTM) United States $0.240B 0.00 Nuvectis Pharma (NVCT) United States $0.240B 0.00 Lifecore Biomedical (LFCR) United States $0.237B 0.00 Mesoblast (MESO) Australia $0.236B 0.00 Fate Therapeutics (FATE) United States $0.236B 0.00 Kamada (KMDA) Israel $0.231B 17.76 Tenaya Therapeutics (TNYA) United States $0.229B 0.00 Vigil Neuroscience (VIGL) United States $0.226B 0.00 Stoke Therapeutics (STOK) United States $0.220B 0.00 Gracell Biotechnologies (GRCL) China $0.219B 0.00 TELA Bio (TELA) United States $0.217B 0.00 Y-mAbs Therapeutics (YMAB) United States $0.216B 0.00 Allakos (ALLK) United States $0.213B 0.00 Akoya Biosciences (AKYA) United States $0.212B 0.00 CorMedix Inc (CRMD) United States $0.212B 0.00 ALX Oncology Holdings (ALXO) United States $0.212B 0.00 Immuneering (IMRX) United States $0.211B 0.00 Rallybio (RLYB) United States $0.210B 0.00 Celcuity (CELC) United States $0.209B 0.00 Gossamer Bio (GOSS) United States $0.209B 0.00 Emergent Biosolutions (EBS) United States $0.204B 0.00 Vaxxinity (VAXX) United States $0.200B 0.00 GENFIT S.A (GNFT) France $0.199B 0.00 X4 Pharmaceuticals (XFOR) United States $0.197B 0.00 Invivyd (IVVD) United States $0.193B 0.00 Renovaro Biosciences (RENB) United States $0.193B 0.00 2seventy Bio (TSVT) United States $0.190B 0.00 Sangamo Therapeutics (SGMO) United States $0.188B 0.00 Omega Therapeutics (OMGA) United States $0.185B 0.00 Orchestra BioMed Holdings (OBIO) United States $0.184B 0.00 XOMA (XOMA) United States $0.181B 0.00 MEREO BIOPHARMA (MREO) United Kingdom $0.180B 0.00 Poseida Therapeutics (PSTX) United States $0.180B 0.00 LianBio (LIAN) United States $0.179B 0.00 Molecular Partners AG (MOLN) Switzerland $0.178B 0.00 Merrimack Pharmaceuticals (MACK) United States $0.176B 0.00 Selecta Biosciences (SELB) United States $0.175B 0.00 InflaRx (IFRX) Germany $0.174B 0.00 Ikena Oncology (IKNA) United States $0.173B 0.00 Mersana Therapeutics (MRSN) United States $0.172B 0.00 Vor Biopharma (VOR) $0.172B 0.00 Praxis Precision Medicines (PRAX) United States $0.170B 0.00 PDS Biotechnology (PDSB) United States $0.169B 0.00 Prima BioMed (IMMP) Australia $0.169B 0.00 Seer (SEER) United States $0.165B 0.00 Mind Medicine (MindMed) (MNMD) United States $0.161B 0.00 Inventiva S.A (IVA) France $0.160B 0.00 Puma Biotechnology (PBYI) United States $0.160B 0.00 Oncolytics Biotech (ONCY) Canada $0.158B 0.00 Gritstone Bio (GRTS) United States $0.155B 0.00 Absci (ABSI) United States $0.154B 0.00 Adverum Biotechnologies (ADVM) United States $0.154B 0.00 Rani Therapeutics Holdings (RANI) United States $0.151B 0.00 Atara Biotherapeutics (ATRA) United States $0.150B 0.00 Design Therapeutics (DSGN) United States $0.149B 0.00 Aadi Bioscience (AADI) United States $0.148B 0.00 Codexis (CDXS) United States $0.147B 0.00 XBiotech (XBIT) United States $0.145B 0.00 INmune Bio (INMB) United States $0.144B 0.00 PepGen (PEPG) United States $0.143B 0.00 Ocean Biomedical (OCEA) United States $0.143B 0.00 Trevi Therapeutics (TRVI) United States $0.138B 0.00 Longboard Pharmaceuticals (LBPH) United States $0.136B 0.00 Eton Pharmaceuticals (ETON) United States $0.133B 0.00 Adocia (ADOCY) France $0.133B 0.00 Decibel Therapeutics (DBTX) United States $0.130B 0.00 ProQR Therapeutics (PRQR) Netherlands $0.129B 0.00 Sorrento Therapeutics (SRNEQ) United States $0.127B 0.00 Theseus Pharmaceuticals (THRX) United States $0.127B 0.00 Opthea (OPT) Australia $0.127B 0.00 Graphite Bio (GRPH) United States $0.127B 0.00 TScan Therapeutics (TCRX) United States $0.127B 0.00 Paratek Pharmaceuticals (PRTK) United States $0.126B 0.00 I-Mab (IMAB) China $0.123B 0.00 DiaMedica Therapeutics (DMAC) United States $0.123B 0.00 Greenwich LifeSciences (GLSI) United States $0.121B 0.00 Bionano Genomics (BNGO) United States $0.119B 0.00 Cue Biopharma (CUE) United States $0.119B 0.00 Seelos Therapeutics (SEEL) United States $0.118B 0.00 Gamida Cell (GMDA) United States $0.118B 0.00 NGM Biopharmaceuticals (NGM) United States $0.115B 0.00 Orchard Therapeutics (ORTX) United Kingdom $0.114B 0.00 Annexon (ANNX) United States $0.114B 0.00 C4 Therapeutics (CCCC) United States $0.114B 0.00 Inovio Pharmaceuticals (INO) United States $0.113B 0.00 Kodiak Sciences (KOD) United States $0.113B 0.00 Ocugen (OCGN) United States $0.112B 0.00 Turnstone Biologics (TSBX) United States $0.112B 0.00 Evelo Biosciences (EVLO) United States $0.112B 0.00 ANIXA BIOSCIENCES INC (ANIX) United States $0.111B 0.00 MediciNova (MNOV) United States $0.108B 0.00 Applied Therapeutics (APLT) United States $0.107B 0.00 ChromaDex (CDXC) United States $0.105B 0.00 Graf Acquisition IV (GFOR) United States $0.104B 0.00 Abeona Therapeutics (ABEO) United States $0.104B 0.00 Milestone Pharmaceuticals (MIST) Canada $0.103B 0.00 Spruce Biosciences (SPRB) United States $0.101B 0.00 Cidara Therapeutics (CDTX) United States $0.101B 0.00 Genenta Science S.p.A (GNTA) Italy $0.100B 0.00 BioXcel Therapeutics (BTAI) United States $0.099B 0.00 Beyond Air (XAIR) United States $0.099B 0.00 Cara Therapeutics (CARA) United States $0.098B 0.00 Cellectis S.A (CLLS) France $0.098B 0.00 PhenomeX (CELL) United States $0.098B 0.00 BioAtla (BCAB) United States $0.098B 0.00 BRIACELL THERAP (BCTX) Canada $0.097B 0.00 Annovis Bio (ANVS) United States $0.095B 0.00 ATyr Pharma (LIFE) United States $0.094B 0.00 IO Biotech (IOBT) Denmark $0.093B 0.00 CytomX Therapeutics (CTMX) United States $0.092B 0.00 Compugen (CGEN) Israel $0.091B 0.00 Immunome (IMNM) United States $0.090B 0.00 Werewolf Therapeutics (HOWL) United States $0.090B 0.00 Axcella Health (AXLA) United States $0.088B 0.00 Shattuck Labs (STTK) United States $0.087B 0.00 Kezar Life Sciences (KZR) United States $0.087B 0.00 Kinnate Biopharma (KNTE) United States $0.086B 0.00 Data Knights Acquisition (DKDCA) United Kingdom $0.085B 0.00 Genetron Holdings (GTH) China $0.083B 0.00 Jasper Therapeutics (JSPR) United States $0.083B 0.00 Anebulo Pharmaceuticals (ANEB) United States $0.082B 0.00 G1 Therapeutics (GTHX) United States $0.082B 0.00 Ocuphire Pharma (OCUP) United States $0.082B 4.64 Syros Pharmaceuticals (SYRS) United States $0.082B 0.00 Nkarta (NKTX) United States $0.080B 0.00 Corvus Pharmaceuticals (CRVS) United States $0.080B 0.00 Clene (CLNN) United States $0.078B 0.00 Cardiff Oncology (CRDF) United States $0.078B 0.00 Affimed (AFMD) Germany $0.077B 0.00 Athira Pharma (ATHA) United States $0.077B 0.00 Elicio Therapeutics (ELTX) United States $0.077B 0.00 Tiziana Life Sciences (TLSA) United Kingdom $0.074B 0.00 Kronos Bio (KRON) United States $0.073B 0.00 HCW Biologics (HCWB) United States $0.073B 0.00 Adicet Bio (ACET) United States $0.071B 0.00 Prenetics Global (PRE) Cayman Islands $0.071B 1.45 ADC Therapeutics SA (ADCT) Switzerland $0.071B 0.00 AVROBIO (AVRO) United States $0.069B 0.00 Spero Therapeutics (SPRO) United States $0.068B 0.00 Intensity Therapeutics (INTS) United States $0.068B 0.00 Eyenovia (EYEN) United States $0.068B 0.00 Vaccitech (VACC) United Kingdom $0.067B 0.00 Enzo Biochem (ENZ) United States $0.067B 0.00 Solid Biosciences (SLDB) United States $0.066B 0.00 Immunic (IMUX) United States $0.066B 0.00 Xilio Therapeutics (XLO) United States $0.065B 0.00 Instil Bio (TIL) United States $0.062B 0.00 Oncobiologics (OTLK) United States $0.061B 0.00 Aeglea BioTherapeutics (AGLE) United States $0.060B 0.00 HOOKIPA Pharma (HOOK) United States $0.060B 0.00 Curis (CRIS) United States $0.060B 0.00 Rezolute (RZLT) United States $0.058B 0.00 VistaGen Therapeutics (VTGN) United States $0.056B 0.00 Celularity (CELU) United States $0.055B 0.00 Brainstorm Cell Therapeutics (BCLI) United States $0.054B 0.00 Clearside Biomedical (CLSD) United States $0.053B 0.00 Dyadic (DYAI) United States $0.052B 0.00 VTv Therapeutics (VTVT) United States $0.051B 0.00 Adagene (ADAG) China $0.051B 0.00 Mainz Biomed (MYNZ) Germany $0.051B 0.00 OKYO Pharma (OKYO) $0.051B 0.00 Alpha Teknova (TKNO) United States $0.050B 0.00 Theratechnologies (THTX) Canada $0.050B 0.00 Precision BioSciences (DTIL) United States $0.049B 0.00 Fortress Biotech (FBIO) United States $0.049B 0.00 Longeveron (LGVN) United States $0.049B 0.00 Coya Therapeutics (COYA) United States $0.047B 0.00 Quince Therapeutics (QNCX) United States $0.047B 0.00 Lantern Pharma (LTRN) United States $0.046B 0.00 Portage Biotech (PRTG) $0.046B 0.00 Immix Biopharma (IMMX) United States $0.045B 0.00 Dare Bioscience (DARE) United States $0.045B 0.00 Leap Therapeutics (LPTX) United States $0.043B 0.00 MiNK Therapeutics (INKT) United States $0.043B 0.00 Galena Biopharma (SLS) United States $0.043B 0.00 Connect Biopharma Holdings (CNTB) United States $0.043B 0.00 Checkpoint Therapeutics (CKPT) United States $0.043B 0.00 Bolt Biotherapeutics (BOLT) United States $0.042B 0.00 Passage Bio (PASG) United States $0.041B 0.00 Cognition Therapeutics (CGTX) United States $0.040B 0.00 CytoMed Therapeutics (GDTC) Singapore $0.039B 0.00 NextCure (NXTC) United States $0.038B 0.00 UNITY Biotechnology (UBX) United States $0.037B 0.00 BeyondSpring (BYSI) United States $0.037B 0.00 Cyclo Therapeutics (CYTH) United States $0.036B 0.00 Telesis Bio (TBIO) United States $0.036B 0.00 Miromatrix Medical (MIRO) United States $0.036B 0.00 Biora Therapeutics (BIOR) United States $0.035B 0.00 Achilles Therapeutics (ACHL) United Kingdom $0.035B 0.00 Aligos Therapeutics (ALGS) United States $0.035B 0.00 Candel Therapeutics (CADL) United States $0.035B 0.00 ASLAN Pharmaceuticals (ASLN) Singapore $0.034B 0.00 NuCana (NCNA) United Kingdom $0.033B 0.00 Neoleukin Therapeutics (NLTX) United States $0.033B 0.00 Science 37 Holdings (SNCE) United States $0.032B 0.00 Pieris Pharmaceuticals (PIRS) United States $0.032B 0.00 Rain Oncology (RAIN) United States $0.032B 0.00 SAB Biotherapeutics (SABS) United States $0.032B 0.00 Elevation Oncology (ELEV) United States $0.031B 0.00 Forte Biosciences (FBRX) United States $0.031B 0.00 GENPREX (GNPX) United States $0.031B 0.00 IN8bio (INAB) United States $0.030B 0.00 Alimera Sciences (ALIM) United States $0.029B 0.00 Eledon Pharmaceuticals (ELDN) United States $0.029B 0.00 Evogene (EVGN) Israel $0.029B 0.00 KALA BIO (KALA) United States $0.028B 0.00 EFFECTOR Therapeutics (EFTR) United States $0.027B 0.00 Equillium (EQ) United States $0.027B 0.00 Liminal BioSciences (LMNL) Canada $0.026B 0.00 Lumos Pharma (LUMO) United States $0.026B 0.00 Pluri (PLUR) Israel $0.026B 0.00 YS Biopharma (YS) China $0.025B 1.24 Senti Biosciences (SNTI) United States $0.025B 0.00 Aptose Biosciences (APTO) Canada $0.025B 0.00 VBI Vaccines (VBIV) United States $0.025B 0.00 Coeptis Therapeutics Holdings (COEP) United States $0.025B 0.00 Alzamend Neuro (ALZN) United States $0.022B 0.00 Acurx Pharmaceuticals (ACXP) United States $0.022B 0.00 Mustang Bio (MBIO) United States $0.021B 0.00 Hepion Pharmaceuticals (HEPA) United States $0.021B 0.00 Purple Biotech (PPBT) Israel $0.021B 0.00 Evaxion Biotech (EVAX) Denmark $0.021B 0.00 Sensei Biotherapeutics (SNSE) United States $0.021B 0.00 Cocrystal Pharma (COCP) United States $0.020B 0.00 Orgenesis (ORGS) United States $0.020B 0.00 Entera Bio (ENTX) Israel $0.020B 0.00 Catalyst Biosciences (CBIO) United States $0.020B 0.00 Medicenna Therapeutics (MDNA) Canada $0.020B 0.00 Kineta (KA) United States $0.019B 0.00 CalciMedica (CALC) United States $0.019B 0.00 Acorda Therapeutics (ACOR) United States $0.018B 0.00 Eiger BioPharmaceuticals (EIGR) United States $0.018B 0.00 Vascular Biogenics (VBLT) Israel $0.018B 0.00 AquaBounty Technologies (AQB) United States $0.018B 0.00 Edesa Biotech (EDSA) Canada $0.018B 0.00 Virios Therapeutics (VIRI) United States $0.018B 0.00 ZIVO Bioscience (ZIVO) United States $0.017B 0.00 Synlogic (SYBX) United States $0.017B 0.00 Novogen (KZIA) Australia $0.017B 0.00 RenovoRx (RNXT) United States $0.017B 0.00 Galecto (GLTO) Denmark $0.017B 0.00 Freeline Therapeutics Holdings (FRLN) United Kingdom $0.017B 0.00 Genetic Technologies (GENE) Australia $0.016B 0.00 Promis Neurosciences (PMN) Canada $0.016B 0.00 Lisata Therapeutics (LSTA) United States $0.016B 0.00 Vincerx Pharma (VINC) United States $0.016B 0.00 TradeUP Acquisition (UPTD) United States $0.016B 0.00 PHAXIAM Therapeutics S.A (PHXM) France $0.016B 0.00 Frequency Therapeutics (FREQ) United States $0.016B 0.00 Aprea Therapeutics (APRE) United States $0.015B 0.00 Bionomics (BNOX) Australia $0.015B 0.00 BioAffinity Technologies (BIAF) United States $0.014B 0.00 GeoVax Labs (GOVX) United States $0.014B 0.00 Atreca (BCEL) United States $0.013B 0.00 Akari Therapeutics (AKTX) United Kingdom $0.013B 0.00 Pasithea Therapeutics (KTTA) United States $0.013B 0.00 TFF Pharmaceuticals (TFFP) United States $0.013B 0.00 Senesco Technologies (ELOX) United States $0.013B 0.00 Vaccinex (VCNX) United States $0.013B 0.00 AEterna Zentaris (AEZS) Canada $0.013B 0.00 NeuroBo Pharmaceuticals (NRBO) United States $0.012B 0.00 Lipella Pharmaceuticals (LIPO) United States $0.012B 0.00 Moleculin Biotech (MBRX) United States $0.012B 0.00 Chemomab Therapeutics (CMMB) Israel $0.012B 0.00 IMMURON (IMRN) Australia $0.011B 0.00 Avalon GloboCare (ALBT) United States $0.011B 0.00 Eterna Therapeutics (ERNA) United States $0.011B 0.00 Biofrontera (BFRI) United States $0.011B 0.00 Talis Biomedical (TLIS) United States $0.011B 0.00 Prana Biotechnology (ATHE) Australia $0.011B 0.00 Blue Water Biotech (BWV) United States $0.011B 0.00 Landos Biopharma (LABP) United States $0.011B 0.00 ARAVIVE, INC (ARAV) United States $0.011B 0.00 Imunon (IMNN) United States $0.011B 0.00 Cadrenal Therapeutics (CVKD) United States $0.010B 0.00 Comera Life Sciences Holdings (CMRA) United States $0.010B 0.00 GT Biopharma (GTBP) United States $0.010B 0.00 Cingulate (CING) United States $0.010B 0.00 Organovo Holdings (ONVO) United States $0.010B 0.00 Athersys (ATHX) United States $0.010B 0.00 Trevena (TRVN) United States $0.009B 0.00 Virpax Pharmaceuticals (VRPX) United States $0.009B 0.00 NeuroSense Therapeutics (NRSN) Israel $0.009B 0.00 Sunshine Biopharma (SBFM) Canada $0.009B 0.00 BioCardia (BCDA) United States $0.009B 0.00 Cyclerion Therapeutics (CYCN) United States $0.009B 0.00 Galera Therapeutics (GRTX) United States $0.009B 0.00 Monopar Therapeutics (MNPR) United States $0.009B 0.00 Applied Molecular Transport (AMTI) United States $0.008B 0.00 Cohbar (CWBR) United States $0.008B 0.00 Pulmatrix (PULM) United States $0.008B 0.00 Creative Medical Technology Holdings (CELZ) United States $0.008B 0.00 Atrinsic (PTIX) United States $0.008B 0.00 Lexaria Bioscience (LEXX) Canada $0.008B 0.00 TRACON Pharmaceuticals (TCON) United States $0.008B 0.00 Aileron Therapeutics (ALRN) United States $0.007B 0.00 Biodexa Pharmaceuticals (BDRX) United Kingdom $0.007B 0.00 Biophytis SA (BPTS) France $0.007B 0.00 Kintara Therapeutics (KTRA) United States $0.007B 0.00 CervoMed (CRVO) United States $0.007B 0.00 Exicure (XCUR) United States $0.007B 0.48 Biorestorative Therapies (BRTX) United States $0.007B 0.00 Titan Pharmaceuticals (TTNP) United States $0.007B 0.00 Tenax Therapeutics (TENX) United States $0.007B 0.00 Sonnet BioTherapeutics Holdings (SONN) United States $0.007B 0.00 CNS Pharmaceuticals (CNSP) United States $0.006B 0.00 Hoth Therapeutics (HOTH) United States $0.006B 0.00 Silo Pharma (SILO) United States $0.006B 0.00 Bright Minds Biosciences (DRUG) United States $0.006B 0.00 Aytu BioPharma (AYTU) United States $0.006B 0.00 ZyVersa Therapeutics (ZVSA) United States $0.006B 0.00 Virax Biolabs Group (VRAX) United Kingdom $0.006B 0.00 Windtree Therapeutics (WINT) United States $0.006B 0.00 Bellerophon Therapeutics (BLPH) United States $0.006B 0.00 Cardio Diagnostics Holdings (CDIO) United States $0.005B 0.00 Ensysce Biosciences (ENSC) United States $0.005B 0.00 NexImmune (NEXI) United States $0.005B 0.00 Benitec Biopharma (BNTC) United States $0.005B 0.00 Enveric Biosciences (ENVB) United States $0.005B 0.00 Femasys (FEMY) United States $0.005B 0.00 Lixte Biotechnology Holdings (LIXT) United States $0.005B 0.00 Revelation Biosciences (REVB) United States $0.005B 0.00 ABVC BioPharma (ABVC) United States $0.005B 0.00 PaxMedica (PXMD) United States $0.005B 0.00 Aptevo Therapeutics (APVO) United States $0.004B 0.00 Palisade Bio (PALI) United States $0.004B 0.05 Artelo Biosciences (ARTL) United States $0.004B 0.00 Panbela Therapeutics (PBLA) United States $0.004B 0.00 GRI Bio (GRI) United States $0.004B 0.00 Soligenix (SNGX) United States $0.004B 0.00 Hillstream BioPharma (HILS) United States $0.004B 0.00 Adial Pharmaceuticals (ADIL) United States $0.004B 0.00 Cyclacel Pharmaceuticals (CYCC) United States $0.004B 0.00 Dermata Therapeutics (DRMA) United States $0.004B 0.00 Synaptogenix (SNPX) United States $0.004B 0.00 Aceragen (ACGN) United States $0.003B 0.00 First Wave BioPharma (FWBI) United States $0.003B 0.09 ThermoGenesis Holdings (THMO) United States $0.003B 0.00 NeuBase Therapeutics (NBSE) United States $0.003B 0.00 180 Life Sciences (ATNF) United States $0.003B 0.22 Invo BioScience (INVO) United States $0.003B 0.00 BiondVax Pharmaceuticals (SCNI) Israel $0.002B 0.00 Bone Biologics (BBLG) United States $0.002B 0.00 Kiromic BioPharma (KRBP) United States $0.002B 0.00 TC BioPharm (Holdings) (TCBP) United Kingdom $0.000B 0.00 MorphoSys AG (MOR) Germany $0.000B 18.42 Regencell Bioscience Holdings (RGC) Hong Kong, SAR China $0.000B 0.00 ARCA Biopharma (ABIO) United States $0.000B 0.00 Alvotech (ALVO) $0.000B 0.00 CollPlant Biotechnologies (CLGN) Israel $0.000B 0.00 Celyad SA (CYAD) Belgium $0.000B 0.00 GH Research (GHRS) Ireland $0.000B 0.00 LAVA Therapeutics (LVTX) Netherlands $0.000B 0.00 Motif Bio Plc (MTFB) United Kingdom $0.000B 0.00 PDL BioPharma (PDLI) United States $0.000B 0.00 Pharvaris (PHVS) Netherlands $0.000B 0.00 VectivBio Holding AG (VECT) Switzerland $0.000B 0.00

Who owns TGTX stock?

Nous, Yahoo, faisons partie de la famille de marques Yahoo.

Lorsque vous utilisez nos sites et applications, nous utilisons des cookies pour :

Who is the founder of TGTX?

Vi, Yahoo, er en del av Yahoo-familien av merkevarer.

Når du bruker våre nettsteder og apper, bruker vi informasjonskapsler for følgende formål:

How many Employees does ADC Therapeutics have?

ADC Therapeutics is a commercial, global leader and pioneer in the field of antibody-drug conjugates (ADCs). We have a fully integrated value chain with specialized capabilities unique to the lifecycle of ADCs including research, translational and chemistry, manufacturing and controls. Our robust pipeline is comprised of ADCs in clinical trials for both hematologic and solid tumor cancers. We have a strong, proven technology platform in highly potent PBD-based ADCs and we are expanding our reach to develop next-generation assets.

Our senior leaders are industry veterans with experience in both large pharmaceutical companies and biotechnology startups and our highly skilled global workforce is committed to transforming the lives of patients with cancer.

We strive to be a leading antibody drug conjugate company that transforms the lives of those impacted by cancer

How many people are employed by beam therapeutics?

CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company has ranked No. 4 on the Boston Globe’s 2022 Top Places to Work in the “Large Companies” category, marking its fourth consecutive year as an honoree.

The Boston Globe’s Top Places to Work, which will be featured in the print edition of Sunday’s paper, recognizes the most admired workplaces in the state, voted on by the people who know them best – their employees. The survey measures employee opinions about their company's leadership, appreciation, benefits and more. The winners are divided into four categories based on the number of employees: small (50-99); medium (100-249); large (250-999); and largest (1,000 or more). More than 94,000 employees at 381 companies completed surveys this year—a record high.

Is TG a good stock to buy?

Zacks' proprietary data indicates that TG Therapeutics, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the TGTX shares relative to the market in the next few months. In addition, TG Therapeutics, Inc. has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading style). Valuation metrics show that TG Therapeutics, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of TGTX, demonstrate its potential to underperform the market. It currently has a Growth Score of D. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of F.

How high will TGTX stock go?

As of 2023 September 15, Friday current price of TGTX stock is 10.165$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).

TG Therapeutics stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame.

Our site uses a custom algorithm based on Deep Learning that helps our users to decide if TGTX could be a bad portfolio addition. These predictions take several variables into account such as volume changes, price changes, market cycles, similar stocks.

Is TGTX a good stock?

The TG Therapeutics stock price gained 0.592% on the last trading day (Thursday, 14th Sep 2023), rising from $10.13 to $10.19. During the last trading day the stock fluctuated 3.29% from a day low at $10.04 to a day high of $10.37. The price has risen in 7 of the last 10 days but is still down by -3.78% for this period. Volume fell on the last day by -1 million shares and in total, 2 million shares were bought and sold for approximately $24.01 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

Ready to grow your portfolio? Here's your free beginner's guide to buying TGTX stock.

Is TGTX a good stock to buy?

Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding TG Therapeutics is 'Hold'. Macroaxis provides TG Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding TGTX positions. The advice algorithm takes into account all of TG Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.

The TGTX recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on TG Therapeutics. Macroaxis does not own or have any residual interests in TG Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute TG Therapeutics' advice using the current market data and latest reported fundamentals.

Enterprise ValueAverage Equity224.9M487.1M268.0M1.1B6.6B2.4B1.7B1.6B65.2M81.4M70.6M11.3M220.7M344.3M114.6M119.3M100%

How big is the ADC market?

New York, United States , May 30, 2023 (GLOBE NEWSWIRE) -- The Global Antibody Drug Conjugates Market Size is to grow from USD 8.6 Billion in 2022 to USD 23.9 billion by 2032, at a Compound Annual Growth Rate (CAGR) of 10.7% during forecast period.

Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/1954

Who owns ADC Therapeutics?

Ameet Mallik joined ADC Therapeutics in May 2022 and has over 25 years of industry experience. Before joining ADC Therapeutics, he served as CEO of Rafael Holdings, a novel cancer and immune metabolism therapeutics company.

Prior to Rafael Holdings, Mr. Mallik spent more than 16 years at Novartis where he served as Executive Vice President and Head, U.S. Oncology from November 2017 through April 2021. Prior to this position, Mr. Mallik served Novartis Oncology as Global Head, Marketing, Value and Access, and Head, Latin America and Canada. Mr. Mallik began his career at Novartis as Head of Strategic Planning and has held a number of commercial and leadership roles at Novartis and Sandoz. At Sandoz, Mr. Mallik was Global Head of Biopharmaceuticals & Oncology Injectables. Before working in pharma, Mr. Mallik was an Associate Principal at McKinsey & Company. He currently serves on the boards of directors of ADC Therapeutics and Atara Biotherapeutics.

Is Beam Therapeutics a good buy?

Zacks' proprietary data indicates that Beam Therapeutics Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the BEAM shares relative to the market in the next few months. In addition, Beam Therapeutics Inc. has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading style). Valuation metrics show that Beam Therapeutics Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of BEAM, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of A.

How big is Beam Therapeutics?

Founded in 2017, the company traces its origins to the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Co-founders include David R. Liu and Feng Zhang.[4] Prior to its IPO, the company raised nearly $1 billion in venture capital from investors. In a February 2020 IPO, the company raised $180 million.[5]

In January 2022, Pfizer and Beam Therapeutics announced a collaboration to develop therapies for rare diseases using CRISPR.[6][7]

How high will TGTX go?

Over the next 52 weeks, TG Therapeutics has on average historically risen by 4.4% based on the past 27 years of stock performance.
TG Therapeutics has risen higher in 11 of those 27 years over the subsequent 52-week period, corresponding to a historical accuracy of 40.74%
Is TG Therapeutics Stock Undervalued? The current TG Therapeutics [TGTX] share price is $10.19. The Score for TGTX is 13, which is 74% below its historic median score of 50, and infers higher risk than normal.
TGTX is currently trading in the 10-20% percentile range relative to its historical Stock Score levels.

Over the next 52 weeks, TG Therapeutics has on average historically risen by 4.4% based on the past 27 years of stock performance.

Who is allarity Therapeutics?

Allarity Therapeutics is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP ®) technology to refine patient selection and improve clinical outcomes.

What does allarity stand for?

BOSTON and SYDNEY (J) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific ... Get a daily email with the top market-moving news in bullet point format, for free.

Is allarity a publicly traded company?

Publicly traded on NASDAQ, Allarity (ALLR) is headquartered in Boston, MA, while maintaining an R&D facility in Hoersholm, Denmark. Allarity is committed to enhancing patient outcomes through improved decision-making and personalized cancer care. Allarity’s robust pipeline includes five anti-cancer drugs that address significant cancer markets.

How does allarity improve patient outcomes?

Allarity is committed to enhancing patient outcomes through improved decision-making and personalized cancer care. Allarity’s robust pipeline includes five anti-cancer drugs that address significant cancer markets. All programs include a DRP ® companion diagnostic to select patients most likely to respond to treatment.

Who is allarity Therapeutics?

Allarity Therapeutics is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP ®) technology to refine patient selection and improve clinical outcomes.

What does allarity stand for?

BOSTON and SYDNEY (J) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific ... Get a daily email with the top market-moving news in bullet point format, for free.

Is allarity a publicly traded company?

Publicly traded on NASDAQ, Allarity (ALLR) is headquartered in Boston, MA, while maintaining an R&D facility in Hoersholm, Denmark. Allarity is committed to enhancing patient outcomes through improved decision-making and personalized cancer care. Allarity’s robust pipeline includes five anti-cancer drugs that address significant cancer markets.

How does allarity improve patient outcomes?

Allarity is committed to enhancing patient outcomes through improved decision-making and personalized cancer care. Allarity’s robust pipeline includes five anti-cancer drugs that address significant cancer markets. All programs include a DRP ® companion diagnostic to select patients most likely to respond to treatment.